Audentes Therapeutics has provided an update on its drugs in development for myotubular myopathy, Duchenne muscular dystrophy, myotonic dystrophy type 1 and Pompe disease. Duchenne drug AT702 is going to be begin clinical testing at Nationwide Children’s Hospital, USA, in Q4 of 2019. This is designed to treat Duchenne caused by either duplications of exon 2 or mutations in exons 1-5. Audentes also hopes to begin clinical testing for myotonic dystrophy drug AT466 in 2020.
For more information, read Audentes’ press release.